A Phase 2 clinical trial to evaluate the safety and anti-tumor activity of the combination of Vigil EATC and Atezolizumab in women with advanced ovarian cancer.

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 28 Dec 2016

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Atezolizumab (Primary) ; Bi-shRNAfurin-GM-CSF-loaded tumour cell vaccine (Primary)
Indications Ovarian cancer
Focus Adverse reactions; Pharmacodynamics
Sponsors Gradalis

28 Dec 2016 New trial record
21 Dec 2016 According to Gradalis media release, company plans to initiate this trial early in 2017.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com